NCT03708003 2025-12-30
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL
Swiss Cancer Institute
Phase 2 Terminated
Swiss Cancer Institute
M.D. Anderson Cancer Center
Bristol-Myers Squibb
Pfizer
Ono Pharmaceutical Co. Ltd
Celgene